Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alaunos Therapeutics, Inc. TCRT
$0.57
-$0.01 (-2.28%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
141969935.00000000
-
week52high
4.01
-
week52low
0.45
-
Revenue
2922000
-
P/E TTM
-3
-
Beta
0.17785400
-
EPS
-0.18000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Equal-Weight | 04 мая 2022 г. |
| Raymond James | Market Perform | Market Perform | 09 ноя 2021 г. |
| Raymond James | Market Perform | Outperform | 10 авг 2021 г. |
| Raymond James | Outperform | Outperform | 07 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Vieser Jaime | A | 1250000 | 1250000 | 29 ноя 2022 г. |
| Postma Robert W | A | 5000000 | 750000 | 29 ноя 2022 г. |
| Lackey Melinda | A | 185000 | 185000 | 15 сент 2022 г. |
| Wong Michael | A | 50000 | 50000 | 15 сент 2022 г. |
| Srivastava Abhishek K | A | 25000 | 25000 | 15 сент 2022 г. |
| Deniger Drew | A | 305000 | 305000 | 15 сент 2022 г. |
| Boyle Kevin S. Sr. | D | 866250 | 18750 | 30 авг 2022 г. |
| Srivastava Abhishek K | A | 250000 | 250000 | 12 авг 2022 г. |
| Postma Robert W | A | 100000 | 100000 | 22 июн 2022 г. |
| Postma Robert W | A | 1241870 | 40000 | 22 июн 2022 г. |
Новостная лента
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
24 янв 2023 г. в 11:18
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Zacks Investment Research
18 янв 2023 г. в 10:33
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
Zacks Investment Research
30 ноя 2022 г. в 11:17
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Alaunos Therapeutics Still Waiting For Home Run
Seeking Alpha
21 ноя 2022 г. в 14:13
First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete response rates.
New Strong Buy Stocks for November 18th
Zacks Investment Research
18 ноя 2022 г. в 09:10
VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.